샤페론
2,310KRWMarket close of 10/21 (Wed)
Up +1.76%+40KRWMarket close of 10/21 (Wed)
Preliminary value right after the close — replaced by official KRX data tomorrow morningClose of 10/22 (Thu)2,300KRWDown -0.43%
Preliminary · just after the close · replaced by official KRX data tomorrow morning
- Open
- 2,270
- High
- 2,380
- Low
- 2,215
- Day range
- Day range low 2,215 high 2,380, open 2,270, close 2,310, previous close 2,270
- Volume
- 3×10K shares
- 64.39 million KRW 0.35× the 20-session average
Market close of 10/21 (Wed)
Something to check
1 to check: operating loss
Free · no sign-inSource from 2021-05-17
Points to check
- Earningsto check-15.6B KRWOperating income over the last four quarters -15.6B KRW (loss)
- Daily movenot verifiedOnly 15 daily bars to compare, so not verified
- Trading valuenot verifiedNot enough 20-session trading value data, so not verified
The other 3
- Recent filingsnot verified
- Foreign & institutionalnot verified
- Data date10/21 (Wed)Market close
See the full check report
Quarterly results · Q2 2026
- Revenue41.17 million KRW
- vs. year ago
- Turned profitable
- vs. prior quarter
- -37.0%
- Operating income-3.1B KRW
- vs. year ago
- Still a loss
- vs. prior quarter
- Still a loss
- Operating margin-7,565.0%
- vs. year ago
- —
- vs. prior quarter
- -1,957.2 pp
Quarterly operating income trend
As of the latest official close · 2026-10-21Valuation filing date · 2026-08-12Same sector · 제약
Up +0.83%· 57 of 168 stocks up, preferred shares excluded · trading value 730.8B KRW
| Stock | 20D | Change | Trading value |
|---|---|---|---|
| 삼성바이오로직스 | Close over the last 20 sessions +1.5% | Up +1.87% | 166.1B KRW |
| 셀트리온 | Close over the last 20 sessions +9.6% | Up +0.10% | 119.2B KRW |
| 지투지바이오 | Close over the last 20 sessions +27.6% | Up +13.78% | 49.8B KRW |
| 삼익제약 | Close over the last 20 sessions -20.3% | Up +2.58% | 47.2B KRW |
| 유한양행 | Close over the last 20 sessions +11.7% | Up +0.46% | 35.3B KRW |
Schedule
- Q3 report due · 11/16 (Mon) · in 24 days
- Next data 10/23 (Fri) after 08:50
Investor flows, financials and valuation are provided for 369 stocks. These stocks account for about 85% of trading value, about 92% of market capitalisation. Coverage status →
For information only, not a solicitation to invest. Investment decisions and their results are your own responsibility.